Famke Aeffner

10PUBLICATIONS
100CO-AUTHORS
Characterisation of biological macromoleculesCheminformatics and quantitative structure-activity relationshipsMolecular targetsPathology (excl. oral pathology)Disease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 31, 2025
Scientific and Regulatory Policy Committee Points to Consider*: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development.

Famke Aeffner, Brad Bolon, Molly H Boyle

|Sep 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers.

Brian Belmontes, Katherine K Slemmons, Chun Su

|Oct 20, 2023
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.

Olivier Nolan-Stevaux, Cong Li, Lingming Liang

|Jun 03, 2022
Scientific and Regulatory Policy Committee Points to Consider: Primary Digital Histopathology Evaluation and Peer Review for Good Laboratory Practice (GLP) Nonclinical Toxicology Studies.

Thomas Forest, Famke Aeffner, Dinesh S Bangari

|Mar 24, 2022
Scientific and Regulatory Policy Committee Brief Communication: 2019 Survey on Use of Digital Histopathology Systems in Nonclinical Toxicology Studies.

Thomas Forest, Famke Aeffner, Dinesh S Bangari

|Aug 26, 2021
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.

Brian Belmontes, Deepali V Sawant, Wendy Zhong

Pageof 2

Frequent Collaborators

3 joint publications

Vanessa Schumacher

3 joint publications

Thomas Forest

3 joint publications

Daniel Rudmann

2 joint publications

James Fikes